UY38773A - Compuestos y métodos que inhiben eif4e - Google Patents
Compuestos y métodos que inhiben eif4eInfo
- Publication number
- UY38773A UY38773A UY0001038773A UY38773A UY38773A UY 38773 A UY38773 A UY 38773A UY 0001038773 A UY0001038773 A UY 0001038773A UY 38773 A UY38773 A UY 38773A UY 38773 A UY38773 A UY 38773A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- methods
- formula
- eif4e
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona síntesis, formulaciones farmacéuticamente aceptables y usos de los compuestos de acuerdo con la Formula I, o un estereoisómero, tautómero o sal farmacéuticamente aceptable de los mismos. Para la Fórmula I los compuestos X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 y anillos A, B y C son como se definen en la especificación. Los compuestos de la Fórmula I inventiva son inhibidores de eIF4e y encuentran utilidad en cualquier cantidad de aplicaciones terapéuticas, incluyendo pero no limitado a tratamiento de inflamación y varios cánceres.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869662P | 2019-07-02 | 2019-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38773A true UY38773A (es) | 2021-01-29 |
Family
ID=71614984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038773A UY38773A (es) | 2019-07-02 | 2020-07-02 | Compuestos y métodos que inhiben eif4e |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11286268B1 (es) |
| EP (1) | EP3994139A1 (es) |
| JP (1) | JP2022539256A (es) |
| KR (1) | KR20220061945A (es) |
| CN (1) | CN114269756B (es) |
| AR (1) | AR119339A1 (es) |
| AU (1) | AU2020299362A1 (es) |
| BR (1) | BR112021026682A2 (es) |
| CA (2) | CA3188446A1 (es) |
| CL (1) | CL2021003573A1 (es) |
| IL (1) | IL289456A (es) |
| TW (1) | TWI748541B (es) |
| UY (1) | UY38773A (es) |
| WO (1) | WO2021003157A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021003192A1 (en) * | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Methods of treating braf-mutated cancer cells |
| WO2021240337A1 (en) * | 2020-05-27 | 2021-12-02 | Effector Therapeutics, Inc. | Covalent modifiers of eif4e inhibiting compounds |
| CN117337293A (zh) | 2020-12-22 | 2024-01-02 | 弗埃塞股份有限公司 | 固体形式的eif4e抑制剂 |
| WO2024103069A1 (en) * | 2022-11-10 | 2024-05-16 | Ribometrix, Inc. | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF |
| TW202428278A (zh) * | 2022-12-23 | 2024-07-16 | 大陸商南京聖和藥業股份有限公司 | 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| US9540371B2 (en) * | 2013-04-29 | 2017-01-10 | Vanderbilt University | Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1 |
| CN106102775A (zh) | 2014-02-07 | 2016-11-09 | 效应物治疗公司 | 治疗纤维变性疾病的方法 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
-
2020
- 2020-06-30 AU AU2020299362A patent/AU2020299362A1/en active Pending
- 2020-06-30 EP EP20740483.1A patent/EP3994139A1/en active Pending
- 2020-06-30 CN CN202080059936.5A patent/CN114269756B/zh active Active
- 2020-06-30 JP JP2022500099A patent/JP2022539256A/ja active Pending
- 2020-06-30 US US16/916,820 patent/US11286268B1/en active Active
- 2020-06-30 WO PCT/US2020/040299 patent/WO2021003157A1/en unknown
- 2020-06-30 BR BR112021026682A patent/BR112021026682A2/pt unknown
- 2020-06-30 CA CA3188446A patent/CA3188446A1/en active Pending
- 2020-06-30 CA CA3085255A patent/CA3085255A1/en active Pending
- 2020-06-30 TW TW109122116A patent/TWI748541B/zh active
- 2020-06-30 KR KR1020227002902A patent/KR20220061945A/ko unknown
- 2020-07-02 UY UY0001038773A patent/UY38773A/es unknown
- 2020-07-02 AR ARP200101877A patent/AR119339A1/es unknown
-
2021
- 2021-12-28 IL IL289456A patent/IL289456A/en unknown
- 2021-12-30 CL CL2021003573A patent/CL2021003573A1/es unknown
-
2022
- 2022-01-28 US US17/587,185 patent/US20230108594A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230108594A1 (en) | 2023-04-06 |
| CA3188446A1 (en) | 2021-01-07 |
| IL289456A (en) | 2022-02-01 |
| BR112021026682A2 (pt) | 2022-03-15 |
| WO2021003157A1 (en) | 2021-01-07 |
| CN114269756A (zh) | 2022-04-01 |
| EP3994139A1 (en) | 2022-05-11 |
| KR20220061945A (ko) | 2022-05-13 |
| TW202115058A (zh) | 2021-04-16 |
| CL2021003573A1 (es) | 2022-08-12 |
| JP2022539256A (ja) | 2022-09-07 |
| CN114269756B (zh) | 2024-05-14 |
| AU2020299362A1 (en) | 2022-02-24 |
| AR119339A1 (es) | 2021-12-09 |
| US11286268B1 (en) | 2022-03-29 |
| TWI748541B (zh) | 2021-12-01 |
| CA3085255A1 (en) | 2021-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38773A (es) | Compuestos y métodos que inhiben eif4e | |
| CO2018006475A2 (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos | |
| CO2022008091A2 (es) | Inhibidores de kras g12c | |
| CL2017001017A1 (es) | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| UY37007A (es) | Compuestos derivados de purinas, estimuladores de genes de interferón | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CR20130646A (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| CR20190087A (es) | Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| ECSP22038478A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| UY37225A (es) | Inhibidores del potenciador del homólogo zeste 2 campo de la invención | |
| CL2020002139A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. | |
| CL2020000553A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. | |
| CR20170462A (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda | |
| ECSP18056196A (es) | Derivados de indano |